Key Takeaways In legislation enacted on Feb. 3, 2026, Congress reauthorized the rare pediatric disease priority review voucher program, clarified the scope of orphan drug exclusivity (ODE) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results